Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interventional study of maternal hypothyroxinemia and pregnancy/offspring neurodevelopment outcomes
ChiCTR2400088341Phase 4Not yet recruiting
- Sponsor
- Shanghai First Maternal and Infant Health Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of levothyroxine sodium in Hypothyroxinemia (8 arms), sponsored by Shanghai First Maternal and Infant Health Hospital. Primary endpoints: Offspring neurodevelopment (RP V), Premature delivery (RP V) and 2 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
levothyroxine sodium
03
Conditions
Hypothyroxinemia
Beyond the preview
Go deeper on ChiCTR2400088341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088341.